HOME >> MEDICINE >> NEWS
Jefferson scientists create first animal model of common type of leukemia

ct this," he says. "We thought the mice would develop B-cell tumors like B-cell lymphomas, not one specific disease such as B-cell CLL." Dr. Croce and his co-workers at Fox Chase Cancer Center in Philadelphia and the Istituto Dermatopatico dell'Immacolata in Rome report their findings May 14 in the Proceedings of the National Academy of Sciences.

"We really don't know much about the genetic mechanism involved in the pathogenesis of CLL," Dr. Croce says. "What this tells us is that either the TCL-1 gene or another gene (s) in the TCL-1 pathway are involved in the initiation and maintenance of B-cell CLL. Now we can target drugs at TCL-1 or molecules that interact with TCL-1. Eventually, we'll discover other targets in the future now that we know this pathway is important."

According to Dr. Croce, because the mouse disease is nearly identical to human CLL, the model will enable scientists to investigate all of the steps involved in the development of the disease. It will also tell researchers whether - and which - drugs work best early or late in the development of the disease.

B-cell CLL is a disease of apoptosis, or programmed cell death, gone awry, he explains. Leukemia cells are not dividing or dying; instead they continue to live a very long time. The study results should "provide important clues about the regulation of programmed cell death - why leukemic cells don't die," Dr. Croce notes, "and help us understand genetic mechanisms involved."

There are as many as 10,000 new cases of B-cell CLL in the United States each year. The disease often strikes the elderly, and while incurable, is slow growing, often lasting as long as 10 to 20 years.


'"/>

Contact: Steve Benowitz
steven.benowitz@mail.tju.edu
215-955-5291
Thomas Jefferson University
21-May-2002


Page: 1 2

Related medicine news :

1. Jefferson Lab medical imager spots breast cancer
2. Jefferson scientists uncover potential trigger of diabetic kidney disease
3. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
4. Jefferson scientists help explain statins effects in Alzheimers disease
5. Jefferson scientists find zinc may help prevent esophageal, oral cancers
6. Jefferson virologists coax HIV out of hiding
7. Jefferson scientists find way to see breast cancer activity from outside the body
8. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
9. Jefferson scientists use gene therapy to rescue failing hearts in animals
10. Jefferson scientists reveal how some types of rabies invade the brain
11. Jefferson neuroscientists studying new type of Alzheimers drug to halt disease progression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... July 24, 2017 , ... “Journey to the Light: The Quest ... details a young woman’s path to finding herself. “Journey to the Light: The ... author, Jamie Grayson, an experienced writer of newsletters, manuals, and articles, who has recently ...
(Date:7/23/2017)... Pekin, IL (PRWEB) , ... ... ... Association of Eating Disorders Professionals ™(iaedp), the leading provider of education and ... of training in preparation for competency for Traditional Certification: the iaedp™ Core ...
(Date:7/23/2017)... ... July 23, 2017 , ... Better education to coaches ... presenting their work today at the American Orthopaedic Society for Sports Medicine’ ... first one to prospectively document the association between sports specialization and lower extremity ...
(Date:7/23/2017)... ... 2017 , ... “I Am Not Nothin’: The Serpent Handler’s Daughter” is a ... and write and a brokenhearted young soldier who turned to whiskey after his return ... the power of simple faith is the work of published author Tommy G. Robertson, ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora ... grant of US Patent No. 9,038,640 by the United States Patent and Trademark ... together the combination of Switching, Vacuum, and Cooling mechanisms to further increase the ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, ... UTHR ) announced today that it will report its ... on Thursday, July 27, 2017. ... Thursday, July 27, 2017, at 9:00 a.m. Eastern Time.  ... callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology:
Cached News: